PRIVA-PERINDOPRIL ERBUMINE TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

PERINDOPRIL ERBUMINE

Saatavilla:

NORA PHARMA INC

ATC-koodi:

C09AA04

INN (Kansainvälinen yleisnimi):

PERINDOPRIL

Annos:

2MG

Lääkemuoto:

TABLET

Koostumus:

PERINDOPRIL ERBUMINE 2MG

Antoreitti:

ORAL

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0127178001; AHFS:

Valtuutuksen tilan:

CANCELLED POST MARKET

Valtuutus päivämäärä:

2022-07-25

Valmisteyhteenveto

_Priva-PERINDOPRIL ERBUMINE _
_Page 1 of 55 _
PRODUCT MONOGRAPH
PR PRIVA-PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE TABLETS, USP
2 MG, 4 MG AND 8 MG ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NORA PHARMA INC.
1565, Lionel-Boulet Boul.
Varennes, Québec
J3X 1P7
CONTROL NUMBER: 264075
DATE OF PREPARATION:
May 31, 2022
_Priva-PERINDOPRIL ERBUMINE _
_Page 2 of 55 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
..................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
5
ADVERSE REACTIONS
......................................................................................................
13
DRUG INTERACTIONS
......................................................................................................
20
DOSAGE AND ADMINISTRATION
..................................................................................
22
OVERDOSAGE
.....................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 25
STORAGE AND STABILITY
..............................................................................................
28
SPECIAL HANDLING INSTRUCTIONS
............................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 29
PART II: SCIENTIFIC INFORMATION ...................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................